Study of CGEN-15029
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2017
At a glance
- Drugs COM 701 (Primary)
- Indications Autoimmune disorders; Cancer; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Compugen
- 07 Nov 2017 According to a Compugen media release, the company is working on finalizing the clinical protocol and the study is expected to start in 2018.
- 02 Aug 2017 According to a Compugen Ltd. media release, the company is planning to file an IND application towards the end of the first quarter of 2018. Production of the drug for trial and finalizing trial design is ongoing.
- 31 May 2017 According to a Compugen Ltd. media release, the company expects delay of several months in the submission of an Investigational New Drug (IND) application for COM-701 due to contamination of the material manufactured for the GLP toxicity studies during the manufacturing process.